V-Square Quantitative Management’s AstraZeneca AZN Stock Holding History

V-Square Quantitative Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$120K	Sell	631 -159	-20%	-$29.9K	0.01%	532
2026 Q1	$156K	Buy	+790	New	+$152K	0.02%	523

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

V-Square Quantitative Management's AZN Position: Q2 2026 in Review

V-Square Quantitative Management reduced its AstraZeneca (AZN) stake by 20% in Q2 2026, selling an estimated $29.9K and leaving 631 shares worth $120K. The position accounts for 0.01% of the portfolio, ranked #532.

V-Square Quantitative Management first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. The position peaked at $156K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

V-Square Quantitative Management held 631 shares of AstraZeneca worth $120K as of Q2 2026.
V-Square Quantitative Management sold 159 AstraZeneca shares in Q2 2026, an estimated $29.9K.
AstraZeneca made up 0.01% of V-Square Quantitative Management's portfolio in Q2 2026, its #532 holding.
V-Square Quantitative Management first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
V-Square Quantitative Management's AstraZeneca position peaked at $156K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on V-Square Quantitative Management's 13F filing for Q2 2026, filed 27 Jul 2026.